MCID: MCR115
MIFTS: 71

Microvascular Complications of Diabetes 5

Categories: Genetic diseases, Eye diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 5

MalaCards integrated aliases for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 57 75 29 13 6 38 40
Diabetic Retinopathy 38 12 37 29 55 44 15 73
Retinopathy, Diabetic 57 76
Diabetic Nephropathy 75 73
Mvcd5 57 75
Microvascular Complications of Diabetes, Susceptibility to, 5 57
Retinopathy, Diabetic, Susceptibility to 57
Retinal Abnormality - Diabetes-Related 12

Classifications:



External Ids:

OMIM 57 612633
Disease Ontology 12 DOID:8947
ICD9CM 35 362.0
NCIt 50 C34538
MedGen 42 C2674665
KEGG 37 H01457
ICD10 33 H36.0

Summaries for Microvascular Complications of Diabetes 5

UniProtKB/Swiss-Prot : 75 Microvascular complications of diabetes 5: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to severe nonproliferative diabetic retinopathy and background diabetic retinopathy. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and HIF-1 signaling pathway. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include Eye and Eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Diabetic retinopathy, also known as diabetic eye disease, is a medical condition in which damage occurs... more...

Description from OMIM: 612633

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 severe nonproliferative diabetic retinopathy 34.6 ALB INS VEGFA
2 background diabetic retinopathy 34.1 ALB ANGPT2 INS VEGFA
3 microvascular complications of diabetes 3 31.5 ACE AGER AKR1B1 ALB INS
4 microvascular complications of diabetes 1 31.3 ANGPT2 FGF2 FLT1 ICAM1 IGF1 SERPINF1
5 macular retinal edema 30.1 ICAM1 PRKCB SERPINF1 VEGFA
6 macular degeneration, age-related, 1 29.2 FGF2 FLT1 KDR SERPINF1 VEGFA
7 diabetic macular edema 27.8 FGF2 ICAM1 NOS3 PRKCB SERPINF1 TEK
8 microvascular complications of diabetes 2 11.9
9 microvascular complications of diabetes 7 11.8
10 microvascular complications of diabetes 4 10.9
11 microvascular complications of diabetes 6 10.9
12 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 10.9
13 diabetic cataract 10.8 AKR1B1 SERPINF1 VEGFA
14 hypertensive nephropathy 10.7 ACE ALB VEGFA
15 lymphangioma 10.7 KDR SERPINF1 VEGFA
16 skin sarcoidosis 10.7 ACE SERPINF1
17 angiokeratoma circumscriptum 10.7 FLT1 KDR VEGFA
18 autonomic neuropathy 10.6 AKR1B1 ALB INS
19 secondary adrenal insufficiency 10.6 IGF1 INS
20 severe pre-eclampsia 10.6 ALB VCAM1 VEGFA
21 vascular dementia 10.6 ACE PON1 VEGFA
22 epithelioid hemangioendothelioma 10.6 FLT1 KDR VEGFA
23 macular holes 10.6 ANGPT2 SERPINF1 VEGFA
24 ovarian hyperstimulation syndrome 10.6 ALB KDR VEGFA
25 acute hemorrhagic leukoencephalitis 10.6 FLT1 KDR VEGFA
26 rubeosis iridis 10.6 IGF1 INS VEGFA
27 diabetic polyneuropathy 10.6 AGER AKR1B1 VEGFA
28 hemifacial spasm 10.6 NOS3 VEGFA
29 nervous system disease 10.6 ALB INS MIAT VEGFA
30 lipodermatosclerosis 10.6 ANGPT2 FLT1 VEGFA
31 keratopathy 10.6 AKR1B1 IGF1 VCAM1
32 diabetic neuropathy 10.6 ACE AKR1B1 INS VEGFA
33 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.5 IGF1 INS
34 lymphocytic vasculitis 10.5 ICAM1 VCAM1
35 breast carcinoma in situ 10.5 FLT1 KDR VEGFA
36 urinary system disease 10.5 ACE ALB INS
37 ischemic heart disease 10.5 ACE INS NOS3
38 hypoglycemic coma 10.5 INS VEGFA
39 hepatopulmonary syndrome 10.5 ALB NOS3 VEGFA
40 radiation proctitis 10.5 FGF2 KDR VEGFA
41 angiomatous meningioma 10.5 FGF2 KDR VEGFA
42 leukostasis 10.4 ICAM1 KDR VCAM1 VEGFA
43 portal hypertension 10.4 ALB NOS3 VEGFA
44 retinal vein occlusion 10.4 SERPINE1 SERPINF1 VEGFA
45 trypanosomiasis 10.4 ALB ICAM1 VCAM1
46 subendocardial myocardial infarction 10.4 ICAM1 SERPINE1 VCAM1
47 capillary hemangioma 10.3 KDR TEK VEGFA
48 shwartzman phenomenon 10.3 ICAM1 SERPINE1 VCAM1
49 pulmonary edema 10.3 ACE ICAM1 NOS3
50 peripheral artery disease 10.3 ACE NOS3 VCAM1 VEGFA

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM:

612633

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 PRKCB SERPINE1 SERPINF1 TEK VCAM1 VEGFA
2 homeostasis/metabolism MP:0005376 10.48 ACE AGER AKR1B1 ALB ANGPT2 FGF2
3 hematopoietic system MP:0005397 10.41 ICAM1 IGF1 INS KDR NOS3 PRKCB
4 cellular MP:0005384 10.37 AGER ALB ANGPT2 FGF2 FLT1 ICAM1
5 growth/size/body region MP:0005378 10.36 AGER AKR1B1 FLT1 ICAM1 IGF1 INS
6 immune system MP:0005387 10.36 ACE AGER ANGPT2 FLT1 ICAM1 IGF1
7 mortality/aging MP:0010768 10.33 KDR NOS3 SERPINE1 TEK VCAM1 VEGFA
8 muscle MP:0005369 10.17 AGER ALB FGF2 FLT1 ICAM1 IGF1
9 nervous system MP:0003631 10.11 FGF2 FLT1 ICAM1 IGF1 INS KDR
10 integument MP:0010771 10.1 AGER ANGPT2 ICAM1 IGF1 INS KDR
11 liver/biliary system MP:0005370 10.02 ACE ALB INS KDR NOS3 SERPINE1
12 normal MP:0002873 9.97 AGER ALB FLT1 IGF1 INS KDR
13 neoplasm MP:0002006 9.95 ACE ALB FGF2 ICAM1 IGF1 SERPINE1
14 renal/urinary system MP:0005367 9.91 ACE AGER AKR1B1 ALB IGF1 INS
15 reproductive system MP:0005389 9.81 NOS3 SERPINF1 VCAM1 VEGFA ACE FGF2
16 skeleton MP:0005390 9.61 VEGFA AGER AKR1B1 FGF2 IGF1 INS
17 vision/eye MP:0005391 9.36 KDR NOS3 SERPINF1 TEK VEGFA AKR1B1

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 447)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
4
Pioglitazone Approved, Investigational Phase 4,Not Applicable 111025-46-8 4829
5
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
6
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
7
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
8
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
9
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
10
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
11
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
12
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
14
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
15
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
16
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
17
Temazepam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-50-4 5391
18
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
19
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
20
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
21
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5282380 5311221
22
Dipivefrin Approved Phase 4,Not Applicable 52365-63-6 3105
23
Insulin Glargine Approved Phase 4,Phase 3,Early Phase 1 160337-95-1
24
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
25
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
26
Betamethasone Approved, Vet_approved Phase 4,Phase 1 378-44-9 9782
27 Homatropine Approved Phase 4 87-00-3
28
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
29
Copper Approved, Investigational Phase 4,Phase 2 7440-50-8 27099
30
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
31
Brinzolamide Approved Phase 4 138890-62-7 68844
32
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3 90566-53-3 62924
33
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
34
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
35
Interferon beta-1b Approved Phase 4 145155-23-3
36
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
37
Lisinopril Approved, Investigational Phase 4,Not Applicable 83915-83-7, 76547-98-3 5362119
38
Pravastatin Approved Phase 4 81093-37-0 54687
39
Amlodipine Approved Phase 4,Not Applicable 88150-42-9 2162
40
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
41
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Bisoprolol Approved Phase 4 66722-44-9 2405
44
Captopril Approved Phase 4 62571-86-2 44093
45
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
46
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330
47
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
48
Enalaprilat Approved Phase 4 76420-72-9 6917719
49
Eprosartan Approved Phase 4 133040-01-4 5281037
50
Fosinopril Approved Phase 4 98048-97-6 55891

Interventional clinical trials:

(show top 50) (show all 997)
# Name Status NCT ID Phase Drugs
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
2 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
3 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
4 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
5 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
6 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
7 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
8 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
11 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
12 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
13 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
14 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
15 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
16 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
17 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Unknown status NCT02633852 Phase 4 Aflibercept
18 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
19 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
20 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
21 Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema Unknown status NCT02131350 Phase 4 Ranibizumab
22 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
23 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
24 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
25 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
26 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
27 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
28 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
29 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed NCT01594281 Phase 4 Ranibizumab
30 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
31 Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients Completed NCT00174824 Phase 4 Insulin glargine
32 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
33 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
34 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
35 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
36 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
37 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
38 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
39 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
40 VITAL - Individualising Therapy for Neovascular AMD With Aflibercept Completed NCT02441816 Phase 4 Aflibercept
41 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
42 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
43 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
44 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
45 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
46 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
47 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
48 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
49 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
50 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

# Genetic test Affiliating Genes
1 Diabetic Retinopathy 29
2 Microvascular Complications of Diabetes 5 29 PON1

Anatomical Context for Microvascular Complications of Diabetes 5

MalaCards organs/tissues related to Microvascular Complications of Diabetes 5:

41
Eye, Endothelial, Retina, Bone, Testes, Kidney, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Potential therapeutic candidate, affected by disease
2 Eye Outer Nuclear Layer Mature M Cone Cells Potential therapeutic candidate, affected by disease
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Potential therapeutic candidate, affected by disease
5 Eye Outer Nuclear Layer Mature S Cone Cells Potential therapeutic candidate, affected by disease

Publications for Microvascular Complications of Diabetes 5

Articles related to Microvascular Complications of Diabetes 5:

(show top 50) (show all 1809)
# Title Authors Year
1
Metabolomics Analysis of Human Vitreous in Diabetic Retinopathy and Rhegmatogenous Retinal Detachment. ( 29877085 )
2018
2
Venous beading in two or more quadrants might not be a sensitive grading criterion for severe nonproliferative diabetic retinopathy. ( 29626228 )
2018
3
Evaluation of TGF-Beta 2 and VEGF<i>I+</i> Gene Expression Levels in Epiretinal Membranes and Internal Limiting Membranes in the Course of Retinal Detachments, Proliferative Diabetic Retinopathy, Macular Holes, and Idiopathic Epiretinal Membranes. ( 29850215 )
2018
4
Endothelin-1 is associated with fibrosis in proliferative diabetic retinopathy membranes. ( 29351334 )
2018
5
Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema. ( 29896154 )
2018
6
ASYMMETRIC DIABETIC RETINOPATHY PROGRESSION IN PATIENTS WITH AXIAL ANISOMETROPIA. ( 29547453 )
2018
7
Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. ( 29924846 )
2018
8
Successful Management of Proliferative Diabetic Retinopathy and Multiple Choroidal Tubercles in a Patient with Miliary Tuberculosis. ( 29719654 )
2018
9
PHACOEMULSIFICATION CATARACT SURGERY WITH PROPHYLACTIC INTRAVITREAL BEVACIZUMAB FOR PATIENTS WITH COEXISTING DIABETIC RETINOPATHY: A Meta-Analysis. ( 29975344 )
2018
10
Clinical Efficacy and Safety of the EX-PRESS Filtration Device in Patients with Advanced Neovascular Glaucoma and Proliferative Diabetic Retinopathy. ( 29643784 )
2018
11
A longitudinal study of serum insulin-like growth factor-I levels over 6 years in a large cohort of children and adolescents with type 1 diabetes mellitus: A marker reflecting diabetic retinopathy. ( 29663652 )
2018
12
Meta-Analysis on the Association of ALDH2 Polymorphisms and Type 2 Diabetic Mellitus, Diabetic Retinopathy. ( 28208752 )
2017
13
Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy. ( 28336215 )
2017
14
NONHEREDITARY IDIOPATHIC FOVEAL RETINOSCHISIS ASSOCIATED WITH NEW-ONSET PROLIFERATIVE DIABETIC RETINOPATHY. ( 29176525 )
2017
15
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. ( 28272234 )
2017
16
Idiopathic macular telangiectasis type 2 and co-existent diabetic retinopathy. ( 29299346 )
2017
17
Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy? ( 28724696 )
2017
18
Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2. ( 28012783 )
2017
19
Hyperlipidemia-Mediated Increased Advanced Lipoxidation End Products Formation, an Important Factor Associated with Decreased Erythrocyte Glucose-6-Phosphate Dehydrogenase Activity in Mild Nonproliferative Diabetic Retinopathy. ( 27916496 )
2017
20
RELATIONSHIP BETWEEN OBSTRUCTIVE SLEEP APNEA AND THE PRESENCE AND SEVERITY OF DIABETIC RETINOPATHY. ( 28937527 )
2017
21
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
22
ANRIL: A Regulator of VEGF in Diabetic Retinopathy. ( 28122089 )
2017
23
Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy. ( 28680264 )
2017
24
Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARI+. ( 28270521 )
2017
25
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema. ( 28835783 )
2017
26
Common variants of HNF1A gene are associated with diabetic retinopathy and poor glycemic control in normal-weight Japanese subjects with type 2 diabetes mellitus. ( 27445006 )
2017
27
The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population. ( 27935598 )
2017
28
LOW SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR BUT NOT BRAIN-DERIVED NEUROTROPHIC FACTOR GENE VAL66MET POLYMORPHISM IS ASSOCIATED WITH DIABETIC RETINOPATHY IN CHINESE TYPE 2 DIABETIC PATIENTS. ( 27355244 )
2017
29
Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy. ( 27860331 )
2017
30
CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner. ( 28632765 )
2017
31
Endothelial STAT3 Activation Increases Vascular Leakage Through Downregulating Tight Junction Proteins: Implications for Diabetic Retinopathy. ( 27580405 )
2017
32
Circumpapillary retinal nerve fiber layer thickness, anterior lamina cribrosa depth, and lamina cribrosa thickness in neovascular glaucoma secondary to proliferative diabetic retinopathy: a cross-sectional study. ( 28446148 )
2017
33
Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: A meta-analysis. ( 27613596 )
2017
34
Vascular endothelial growth factor (VEGF)-related single nucleotide polymorphisms rs10738760 and rs6921438 are not associated with diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM). ( 29055125 )
2017
35
Transthyretin Exerts Pro-Apoptotic Effects in Human Retinal Microvascular Endothelial Cells Through a GRP78-Dependent Pathway in Diabetic Retinopathy. ( 28950253 )
2017
36
Mitochondrial Haplogroups Affect Severity But Not Prevalence of Diabetic Retinopathy. ( 28245487 )
2017
37
Histone HIST1H1C/H1.2 regulates autophagy in the development of diabetic retinopathy. ( 28409999 )
2017
38
The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy. ( 28372586 )
2017
39
Genome-wide mRNA analysis reveals a TUBD1 isoform profile as a potential biomarker for diabetic retinopathy development. ( 28137601 )
2017
40
A case of pseudoxanthoma elasticum with proliferative diabetic retinopathy. ( 28978321 )
2017
41
Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report. ( 28923115 )
2017
42
The A445C Variant in Apelin Receptor and Diabetic Retinopathy in Tunisian Patients. ( 28182349 )
2017
43
The Association of a Genetic Variant in SCAF8-CNKSR3 with Diabetic Kidney Disease and Diabetic Retinopathy in a Chinese Population. ( 28401168 )
2017
44
Association of ARHGAP22 gene polymorphisms with the risk of type 2 diabetic retinopathy. ( 28544509 )
2017
45
Association of serum levels of anti-myeloperoxidase antibody with retinal photoreceptor ellipsoid zone disruption in diabetic retinopathy. ( 28279572 )
2017
46
Association of IL-6 Gene (-174 and -572 G/C) Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Population. ( 28651253 )
2017
47
MicroRNA-200b Expression in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. ( 28571008 )
2017
48
Association analysis of PPARI^ (p.Pro12Ala) polymorphism with type 2 diabetic retinopathy in patients from north India. ( 27427939 )
2017
49
The expression of the Slit-Robo signal in the retina of diabetic rats and the vitreous or fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. ( 28973045 )
2017
50
Plasma <i>miR-21</i> expression: an indicator for the severity of Type 2 diabetes with diabetic retinopathy. ( 28108673 )
2017

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PON1 NM_000446.6(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh37 Chromosome 7, 94946084: 94946084
2 PON1 NM_000446.6(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh38 Chromosome 7, 95316772: 95316772

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to KEGG:

37
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933
2 HIF-1 signaling pathway hsa04066
3 Renin-angiotensin system hsa04614

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 ANGPT2 FGF2 FLT1 IGF1 INS KDR
2
Show member pathways
13.42 ANGPT2 FGF2 FLT1 IGF1 KDR NOS3
3
Show member pathways
13.32 ALB ANGPT2 IGF1 NOS3 PRKCB SERPINE1
4
Show member pathways
13.3 ANGPT2 FGF2 FLT1 IGF1 KDR PRKCB
5
Show member pathways
13.28 FGF2 FLT1 IGF1 KDR NOS3 PRKCB
6
Show member pathways
13.02 ACE FGF2 FLT1 IGF1 INS KDR
7
Show member pathways
12.91 ANGPT2 FGF2 FLT1 IGF1 INS KDR
8
Show member pathways
12.77 FGF2 IGF1 KDR PRKCB VEGFA
9
Show member pathways
12.75 FGF2 ICAM1 KDR SERPINE1 VCAM1
10
Show member pathways
12.7 FGF2 FLT1 IGF1 KDR PRKCB
11 12.69 ANGPT2 FGF2 FLT1 IGF1 INS KDR
12
Show member pathways
12.66 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
13
Show member pathways
12.62 ANGPT2 FGF2 FLT1 IGF1 INS KDR
14
Show member pathways
12.58 ANGPT2 FGF2 ICAM1 PRKCB VEGFA
15
Show member pathways
12.51 FLT1 IGF1 INS KDR PRKCB
16
Show member pathways
12.43 FLT1 KDR NOS3 PRKCB
17
Show member pathways
12.43 FLT1 KDR NOS3 PRKCB VEGFA
18
Show member pathways
12.39 FGF2 FLT1 KDR VEGFA
19
Show member pathways
12.36 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
20
Show member pathways
12.33 ALB ICAM1 INS SERPINE1
21 12.31 FGF2 IGF1 KDR PRKCB VEGFA
22
Show member pathways
12.19 FGF2 FLT1 KDR NOS3 PRKCB VEGFA
23 12.14 ANGPT2 FGF2 FLT1 KDR TEK
24 12.09 ICAM1 KDR NOS3 VCAM1 VEGFA
25
Show member pathways
12.08 ANGPT2 FGF2 FLT1 ICAM1 IGF1 KDR
26
Show member pathways
12.07 FLT1 KDR TEK
27 12 FGF2 ICAM1 VCAM1 VEGFA
28 11.92 ALB FGF2 IGF1 INS KDR VCAM1
29
Show member pathways
11.89 FLT1 KDR NOS3 VEGFA
30 11.87 ICAM1 PRKCB VCAM1
31 11.87 FLT1 ICAM1 TEK VEGFA
32
Show member pathways
11.83 FLT1 KDR NOS3 PRKCB
33 11.83 ANGPT2 FGF2 FLT1 KDR NOS3 TEK
34 11.78 FGF2 IGF1 VEGFA
35 11.7 AGER INS NOS3 PRKCB
36 11.7 AGER ICAM1 NOS3 PRKCB SERPINE1 VCAM1
37 11.68 FGF2 IGF1 VEGFA
38
Show member pathways
11.67 ICAM1 VCAM1 VEGFA
39 11.58 FGF2 IGF1 INS KDR
40 11.55 FGF2 KDR VEGFA
41 11.52 FGF2 KDR VEGFA
42 11.51 FGF2 IGF1 INS VEGFA
43 11.5 ICAM1 NOS3 VCAM1
44
Show member pathways
11.47 INS KDR VEGFA
45 11.43 FGF2 FLT1 KDR VEGFA
46 11.4 IGF1 INS PRKCB
47 11.4 ANGPT2 SERPINE1 VEGFA
48 11.37 ICAM1 PRKCB VCAM1
49 11.31 FLT1 KDR SERPINE1 VEGFA
50 11.28 ANGPT2 FLT1 IGF1 INS NOS3 PRKCB

GO Terms for Microvascular Complications of Diabetes 5

Cellular components related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ACE AGER ALB ANGPT2 FGF2 FLT1
2 extracellular space GO:0005615 9.47 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
3 platelet alpha granule lumen GO:0031093 9.46 ALB IGF1 SERPINE1 VEGFA
4 plasma membrane GO:0005886 10.07 ACE AGER ANGPT2 FLT1 ICAM1 IGF1

Biological processes related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.96 FGF2 FLT1 KDR TEK
2 positive regulation of protein phosphorylation GO:0001934 9.95 AGER KDR TEK VEGFA
3 positive regulation of cell migration GO:0030335 9.95 FLT1 IGF1 INS KDR VEGFA
4 extracellular matrix organization GO:0030198 9.93 FGF2 ICAM1 KDR SERPINE1 VCAM1
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 AGER ICAM1 INS PRKCB
6 negative regulation of apoptotic process GO:0043066 9.92 AKR1B1 ALB FLT1 IGF1 INS KDR
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 AGER FGF2 FLT1 ICAM1 KDR TEK
8 platelet degranulation GO:0002576 9.89 ALB IGF1 SERPINE1 VEGFA
9 response to organic substance GO:0010033 9.88 AKR1B1 IGF1 INS TEK
10 positive regulation of MAPK cascade GO:0043410 9.88 FLT1 IGF1 INS KDR TEK
11 response to glucose GO:0009749 9.86 ANGPT2 IGF1 INS
12 response to insulin GO:0032868 9.86 ICAM1 IGF1 INS
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 ICAM1 IGF1 INS VEGFA
14 positive regulation of kinase activity GO:0033674 9.85 FLT1 KDR TEK
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 FLT1 KDR VEGFA
16 positive regulation of MAP kinase activity GO:0043406 9.84 FGF2 FLT1 VEGFA
17 response to nutrient levels GO:0031667 9.84 IGF1 INS PON1
18 vasculogenesis GO:0001570 9.83 FLT1 KDR VEGFA
19 positive regulation of endothelial cell migration GO:0010595 9.82 KDR TEK VEGFA
20 positive regulation of endothelial cell proliferation GO:0001938 9.81 FGF2 KDR TEK VEGFA
21 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.79 ICAM1 NOS3 SERPINE1
22 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.79 FGF2 KDR VEGFA
23 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.76 FGF2 FLT1 TEK
24 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 FGF2 KDR NOS3 VEGFA
25 positive regulation of focal adhesion assembly GO:0051894 9.74 KDR TEK VEGFA
26 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 ICAM1 KDR SERPINE1 TEK
27 induction of positive chemotaxis GO:0050930 9.7 AGER VEGFA
28 negative regulation of wound healing GO:0061045 9.7 FGF2 SERPINE1
29 negative regulation of calcium ion transport GO:0051926 9.7 ICAM1 NOS3
30 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.7 FLT1 PRKCB VEGFA
31 response to hypoxia GO:0001666 9.7 AGER ANGPT2 ICAM1 PRKCB TEK VCAM1
32 positive regulation of positive chemotaxis GO:0050927 9.69 KDR VEGFA
33 vascular endothelial growth factor signaling pathway GO:0038084 9.69 FLT1 KDR
34 positive regulation of phospholipase C activity GO:0010863 9.68 FGF2 FLT1
35 cell migration involved in sprouting angiogenesis GO:0002042 9.67 FGF2 KDR VEGFA
36 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.67 FLT1 KDR VCAM1 VEGFA
37 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 FLT1 IGF1 INS KDR TEK
38 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.64 ACE VEGFA
39 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.64 KDR VEGFA
40 membrane to membrane docking GO:0022614 9.63 ICAM1 VCAM1
41 glomerulus vasculature development GO:0072012 9.63 ANGPT2 TEK
42 Tie signaling pathway GO:0048014 9.6 ANGPT2 TEK
43 angiogenesis GO:0001525 9.56 ANGPT2 FGF2 FLT1 KDR NOS3 SERPINE1
44 positive regulation of angiogenesis GO:0045766 9.28 ANGPT2 FGF2 FLT1